Loading viewer...
investor_presentation
Format: PDF investor_presentation
Virpax Pharmaceuticals is developing differentiated non-addictive treatment options in pain management and related multi-billion-dollar markets through collaborations with the NIH and Department of Defense. The company's lead candidate, Probudur, targets postoperative pain management, with two additional pain assets anticipated to enter human trials in 2024.
investor_presentation
29 Pages
investor_presentation
46 Pages
Humble Group AB